Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non-Current Debt (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Non-Current Debt for 8 consecutive years, with $163.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt fell 60.0% year-over-year to $163.1 million, compared with a TTM value of $163.1 million through Dec 2025, down 60.0%, and an annual FY2025 reading of $214.9 million, down 45.35% over the prior year.
  • Non-Current Debt was $163.1 million for Q4 2025 at Arrowhead Pharmaceuticals, down from $214.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $407.8 million in Q4 2024 and bottomed at $163.1 million in Q4 2025.